Each tablet contains Cilnidipine 10 mg + Olmesartan 20 mg or 40 mg.

Nulong OL Tablets combine Cilnidipine, a dual L/N-type calcium channel blocker, with Olmesartan, an angiotensin II receptor blocker (ARB), to provide effective once-daily management of hypertension. Cilnidipine produces sustained vasodilation while reducing sympathetic nervous system activity, whereas Olmesartan blocks the vasoconstrictor effects of angiotensin II, resulting in reduced peripheral vascular resistance and improved blood pressure control. This complementary combination offers long-lasting antihypertensive efficacy and cardiovascular protection.

Nulong OL Tablets are indicated for the treatment of essential hypertension in adult patients requiring combination antihypertensive therapy.

Cilnidipine is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle cells, producing vasodilation and reducing peripheral vascular resistance. Its additional blockade of N-type calcium channels suppresses sympathetic nerve activity, contributing to sustained blood pressure reduction. Olmesartan is a selective angiotensin II type 1 (AT1) receptor antagonist that blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by preventing its binding to AT1 receptors in vascular smooth muscle. Together, these complementary mechanisms provide effective and prolonged antihypertensive action.

The recommended dosage is one tablet once daily in the morning, or as directed by the physician. The tablet should be taken consistently at the same time each day to maintain optimal blood pressure control.

Nulong OL Tablets are contraindicated in patients with known hypersensitivity to Cilnidipine, Olmesartan, or any component of the formulation, and in patients with aortic stenosis.